Wave Life Sciences (NASDAQ:WVE) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Wave Life Sciences (NASDAQ:WVE) in a report released on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $26.00 price target on the stock. Jefferies Financial Group’s price target suggests a potential upside of 148.09% from the company’s current price.

Several other research analysts have also recently issued reports on WVE. StockNews.com cut Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, November 13th. Truist Financial boosted their target price on Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Mizuho boosted their target price on Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. B. Riley boosted their price objective on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Wave Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Stock Performance

Shares of Wave Life Sciences stock opened at $10.48 on Tuesday. Wave Life Sciences has a 52 week low of $4.25 and a 52 week high of $16.74. The stock has a 50 day moving average price of $11.98 and a two-hundred day moving average price of $10.98. The stock has a market capitalization of $1.60 billion, a PE ratio of -9.44 and a beta of -1.09.

Institutional Investors Weigh In On Wave Life Sciences

Several large investors have recently made changes to their positions in the company. Maverick Capital Ltd. increased its holdings in shares of Wave Life Sciences by 31.0% in the third quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock worth $82,390,000 after purchasing an additional 2,378,159 shares during the last quarter. Driehaus Capital Management LLC grew its position in Wave Life Sciences by 14.6% in the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company’s stock worth $83,033,000 after acquiring an additional 853,589 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Wave Life Sciences by 63.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company’s stock worth $63,074,000 after acquiring an additional 1,972,262 shares in the last quarter. Vanguard Group Inc. grew its position in Wave Life Sciences by 10.2% in the fourth quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company’s stock worth $39,368,000 after acquiring an additional 294,956 shares in the last quarter. Finally, Emerald Advisers LLC grew its position in Wave Life Sciences by 9.7% in the fourth quarter. Emerald Advisers LLC now owns 3,162,369 shares of the company’s stock worth $39,119,000 after acquiring an additional 280,859 shares in the last quarter. 89.73% of the stock is owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.